Product Description
cysteine-rich whey protein isolate formulation (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT01046383)
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Immunotec
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Non-Small-Cell Lung Cancer|Weight Loss
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| IMN1207-07 | P3 |
Terminated |
Weight Loss|Non-Small-Cell Lung Cancer |
2012-06-01 |
2019-03-19 |
Recent News Events
Date |
Type |
Title |
|---|